Company / SG&A Expense
RHYTHM PHARMACEUTICALS, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$194.9M
FY2025
5-year range
$68.5M / $194.9M
FY2021-FY2025
Trend
+35.1%
vs FY2024
Sector context
#71 of 213
Health Care
What the data says
At $195M, RHYTHM PHARMACEUTICALS, INC.'s sg&a expense ranks #143 of 213 in the Health Care sector. SG&A Expense has increased for 9 consecutive years, from $6M in FY2016 to $195M in FY2025.
Based on SEC 10-K filings.
$195M in FY2025 with a 5-year CAGR of +33.4%.
Increased from $118M to $195M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +28.4%
- 5-Year CAGR
- +33.4%
- 10-Year CAGR
- -
Sector benchmark
#143 of 213 in Health CareTop 67% of 213This company $194.9M Sector average $722.3M
▼
-73.0% below sector average
Key checks
Key Insights
- RHYTHM PHARMACEUTICALS, INC.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +33.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 35.1% year-over-year.
- Ranks #71 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $194.9M | +35.1% |
| FY2024 | $144.3M | +22.8% |
| FY2023 | $117.5M | +27.7% |
| FY2022 | $92.0M | +34.4% |
| FY2021 | $68.5M | +48.5% |
| FY2020 | $46.1M | +26.2% |
| FY2019 | $36.5M | +30.2% |
| FY2018 | $28.1M | +195.0% |
| FY2017 | $9.5M | +50.8% |
| FY2016 | $6.3M | +84.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026